Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

The raging bull market that started at the beginning of 2023 is in jeopardy. The recent market downturn is an excellent ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

but the sheer size of Humira makes that a tough task. Newer products such as blood cancer drug Imbruvica (ibrutinib) – which brought in almost $3 billion last year – and hepatitis C virus ...

Nonetheless, the pricing of Humira biosimilars from Sandoz ... for its C-met-targeting lung cancer ADC Emrelis.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Humira accounted for 58% of sales in 2019 ... The ImmunoGen deal's star is the ovarian cancer drug Elahere, which had sales of $479 million in 2024. AbbVie is in the process of expanding its ...

Humira (AbbVie) — $14.4 billion (U.S. 2023 ... HIV treatment — it's the financial backbone for Gilead's move into cancer research," Stanford said. Dr. Jacob Glanville, CEO of Centivax, a ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big ...

However, Skyrizi and Rinvoq, AbbVie’s (NYSE:ABBV) answers to the Humira patent cliff ... However, blood cancer drug Venclexta brought in $665M with ~8% YoY growth, and the antibody-drug ...